356 research outputs found

    Siempre UCM! Recorrido de los doctores egresados por la Facultad de Ciencias Políticas y Sociología

    Get PDF
    Se plantea un proyecto aplicado para mantener el contacto con los egresados en los programas de doctorado de la UCM. Se ha realizado un piloto consistente en la aplicación de un cuestionario. Con esta herramienta se obtiene información sobre publicaciones de egresados que es necesaria para reacreditación y autoinformes, además de información sobre satisfacción con el programa e inserción profesional de utilidad para guiar las decisiones de las comisiones académicas

    Optical design for MEGARA: a multi-object spectrograph for the GTC

    Get PDF
    MEGARA is a multi-object spectrograph project for the 10.4m Gran Telescopio Canarias with medium to high resolution: R ~ 5600 - 17000. The instrument operates in three modes that cover different sky areas and that can run simultaneously: (1) the compact mode through a large central Integral Field Unit with minimum fiber pitch, covering a field of view on sky of 12 arcsec × 14 arcsec, (2) the sparse mode with fibers covering 1 arcmin × 1arcmin in three pointings and (3) the dispersed mode with a grid of nearly 100 robotics positioners able to place 7-fiber minibundles over a large field of view of 3.5 arcmin × 3.5 arcmin. The spectrograph is composed by a pseudo-slit, where the fibers are placed simulating a long slit; a slit shutter is placed just behind the pseudo-slit, a collimator, a 162mm pupil where the volume phase holographic gratings are placed, and the camera with the detector. Here we describe the spectrograph optical rationale, the conceptual optical design and the expected system performance

    MEGARA Optical design: the new integral field unit and multi-object spectrograph for the GTC 10m telescope

    Get PDF
    We describe the optical design of MEGARA, the future optical Integral Field Unit (IFU) and Multi-Object Spectrograph (MOS) for the 10.4-m Gran Telescopio CANARIAS (GTC). MEGARA is being built by a Consortium of public research institutions led by the Universidad Complutense de Madrid (UCM, Spain) that also includes INAOE (Mexico), IAA-CSIC (Spain) and UPM (Spain)

    Analysis of Strength and Endurance Values in Schoolchildren Aged 7 to 10 Years in Tolú, Colombia

    Get PDF
    The objective of this study was to describe the state of strength and endurance in schoolchildren aged 7 to 10 years old from the city of Santiago de Tolú, Colombia, and to relate such values to their weights, heights, and body mass index (BMI) values. This was a descriptive, correlational, cross-sectional research study, whose quantitative statistical analysis was compared with studies conducted in Colombia and other countries. Strength was measured by the summation of the segmental dynamometry of the upper and lower limbs, and endurance was measured with a 5 min continuous run test. This is the first investigation to characterize variables related to physical education and sport in schoolchildren from Tolú. The information collected on the evaluated population may aid in its sustainable human development, since significant differences in height, weight, BMI, strength, and endurance were identified with respect to other national and international populations.This research was supported by the company PREVISERD LTDA in the evaluation of the subjects

    A randomized, double-blind study on the efficacy of oral domperidone versus placebo for reducing SARS-CoV-2 viral load in mild-to-moderate COVID-19 patients in primary health care

    Get PDF
    15 p.-3 fig.-3 tab.Introduction:The clinical effect of domperidone against COVID-19 has been investigated in a double-blind phase III clinical trial (EudraCT number 2021-001228-17). Domperidone has shown in vitro antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and potential immudolatory properties through the stimulation of prolactin secretion.Patients and methods:The efficacy of oral domperidone plus standard of care (SOC; n = 87) versus placebo plus SOC (n = 86) was evaluated in a 28-day randomized double-blind multicentre study in primary health care centres. A total of 173 outpatients with mild-to-moderate COVID-19 were included. Three daily doses of 10 mg (30 mg/day) of domperidone or placebo were administered for 7 days. Reduction of viral load on day 4 was the primary efficay endpoint. It was estimated in saliva samples by reverse transcription-quantitative polymerase chain reaction (RT-qPCR), as the cycle thresholds detected ORF1ab, N Protein and S Protein genes.Results:A significant reduction in the viral load was observed (p < 0.001) from baseline to days 4, 7 and 14 of the three genes studied with non-significant differences between domperidone and placebo groups. Twenty-three patients (13.3%) experienced adverse events, 14 patients in the domperidone group (16.1%) and 9 patients in the placebo group (10.5%). No patients needed to be hospitalized.Conclusion: Results do not prove the use of domperidone as antiviral in patients with COVID-19.This research was funded by CSIC (grant no. PIE 201980E024) and by the European Commission: NextGeneration EU (Regulation EU 2020/2094) through CSIC’s Global Health Platform (PTI Salud Global). The study sponsor was Agencia Estatal Consejo Superior de Investigaciones Científicas, M.P. (CSIC), Madrid, Spain. The sponsor was involved in the design, data interpretation, manuscript review and the decision to submit the article for publication.Peer reviewe
    corecore